Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Return on Equity (2016 - 2021)

Historic Return on Equity for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to 2.93%.

  • Avadel Pharmaceuticals' Return on Equity rose 35500.0% to 2.93% in Q3 2022 from the same period last year, while for Sep 2022 it was 2.93%, marking a year-over-year increase of 35500.0%. This contributed to the annual value of 0.71% for FY2021, which is 6200.0% down from last year.
  • As of Q3 2022, Avadel Pharmaceuticals' Return on Equity stood at 2.93%, which was up 35500.0% from 1.88% recorded in Q2 2022.
  • Avadel Pharmaceuticals' 5-year Return on Equity high stood at 28.25% for Q1 2019, and its period low was 51.18% during Q1 2020.
  • Moreover, its 5-year median value for Return on Equity was 0.21% (2020), whereas its average is 0.82%.
  • Per our database at Business Quant, Avadel Pharmaceuticals' Return on Equity tumbled by -794300bps in 2020 and then skyrocketed by 511800bps in 2021.
  • Over the past 5 years, Avadel Pharmaceuticals' Return on Equity (Quarter) stood at 2.78% in 2018, then surged by 197bps to 2.71% in 2019, then tumbled by -99bps to 0.04% in 2020, then crashed by -2666bps to 1.0% in 2021, then surged by 395bps to 2.93% in 2022.
  • Its Return on Equity stands at 2.93% for Q3 2022, versus 1.88% for Q2 2022 and 1.08% for Q1 2022.